SNY on Nasdaq

Sanofi

Logo: Sanofi, Public domain, via Wikimedia Commons⁴

French multinational pharmaceutical and healthcare company

Price unavailable

Last updated Oct 16, 2026.

Overview

7.9BNet income, fiscal 2025⁵

Aug 20, 2004Founded¹

Compare with another stock.

TickerSNY on Nasdaq¹
Industrypharmaceutical industry¹
HeadquartersParis¹
Websitewww.sanofi.com
Legal formpublic limited company with a board of directors (n.o.s.)¹
Listed onEuronext Paris (SAN), New York Stock Exchange (SNY)¹
Slogan“Empowering life”¹
Incorporated inFrance⁶
Business address46 Avenue De La Grande Armee, Paris, I0 75017⁶
Filer categoryLarge accelerated filer⁶

See how the biggest companies compare on our leaderboards

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000.³

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

10.9%Return on equity⁵

Financial statements

Gross profit⁸⁹¹⁰¹¹¹²⁵$33.7B in 2025+39% since 2018

Operating income⁸⁹¹⁰¹¹¹²⁵$6.3B in 2025+36% since 2018

Net income⁸⁹¹⁰¹¹¹²⁵$7.9B in 2025+78% since 2018

Every line of the income statement in the latest annual report, as filed.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Net sales	43.6B EUR	41.1B EUR	37.8B EUR
Other revenues	3.1B EUR	3.2B EUR	3.8B EUR
Cost of sales	-13.0B EUR	-13.2B EUR	-12.6B EUR
Gross profit	33.7B EUR	31.1B EUR	29.0B EUR
Research and development expenses	-7.8B EUR	-7.4B EUR	-6.5B EUR
Selling and general expenses	-9.5B EUR	-9.2B EUR	-8.9B EUR
Other operating income	1.2B EUR	1.1B EUR	979.0M EUR
Other operating expenses	-5.7B EUR	-4.4B EUR	-3.4B EUR
Amortization of intangible assets	-1.8B EUR	-1.7B EUR	-1.9B EUR
Impairment of intangible assets	-2.2B EUR	-248.0M EUR	-896.0M EUR
Fair value remeasurement of contingent consideration	-104.0M EUR	-96.0M EUR	-93.0M EUR
Restructuring costs and similar items	-1.1B EUR	-1.4B EUR	-1.0B EUR
Other gains and losses, and litigation	-255.0M EUR	-470.0M EUR	-196.0M EUR
Operating income	6.3B EUR	7.3B EUR	7.0B EUR
Financial expenses	-563.0M EUR	-1.1B EUR	-1.3B EUR
Financial income	394.0M EUR	519.0M EUR	584.0M EUR
Income before tax and investments accounted for using the equity method	6.2B EUR	6.7B EUR	6.3B EUR
Income tax expense	-1.0B EUR	-1.2B EUR	-1.0B EUR
Share of profit/(loss) from investments accounted for using the equity method	-155.0M EUR	60.0M EUR	-136.0M EUR
Net income from continuing operations	5.0B EUR	5.6B EUR	5.1B EUR
Net income excluding the exchanged/held-for-exchange Animal Health business	2.9B EUR	64.0M EUR	338.0M EUR
Net income	7.9B EUR	5.6B EUR	5.4B EUR
Net income attributable to non-controlling interests	38.0M EUR	58.0M EUR	36.0M EUR
Net income attributable to equity holders of Sanofi	7.8B EUR	5.6B EUR	5.4B EUR
Average number of shares outstanding (in shares)	1.2B shares	1.3B shares	1.3B shares
Average number of shares after dilution (in shares)	1.2B shares	1.3B shares	1.3B shares
Basic earnings per share excluding the exchanged/held-for-exchange Animal Health business (in euros per share)	4.05 EUR	4.40 EUR	4.06 EUR
Diluted earnings per share (in euros per share)	4.03 EUR	4.39 EUR	4.05 EUR
Basic earnings (loss) per share from discontinued operations	2.35 EUR	0.04 EUR	0.25 EUR
Basic earnings (loss) per share	6.40 EUR	4.44 EUR	4.31 EUR
Diluted earnings (loss) per share from discontinued operations	2.34 EUR	0.04 EUR	0.25 EUR
Diluted earnings (loss) per share	6.37 EUR	4.43 EUR	4.30 EUR

Total assets⁸⁹¹⁰¹¹¹²⁵$126.8B in 2025+14% since 2018

Shareholders’ equity⁹¹⁰¹¹¹²⁵$71.7B in 2025+21% since 2018

Cash⁹¹⁰¹¹¹²⁵$7.7B in 2025+11% since 2018

Every line of the balance sheet in the latest annual report, as filed.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Property, plant and equipment	10.1B EUR	10.1B EUR	10.2B EUR
Right-of-use assets	1.5B EUR	1.5B EUR	1.7B EUR
Goodwill	41.3B EUR	43.4B EUR	49.4B EUR
Other intangible assets	26.3B EUR	22.6B EUR	24.3B EUR
Investments accounted for using the equity method	3.3B EUR	316.0M EUR	424.0M EUR
Other non-current assets	4.4B EUR	3.8B EUR	3.2B EUR
Non-current income tax assets	550.0M EUR	560.0M EUR	188.0M EUR
Deferred tax assets	8.6B EUR	8.0B EUR	6.4B EUR
Non-current assets	95.9B EUR	90.2B EUR	95.8B EUR
Inventories	10.2B EUR	9.4B EUR	9.7B EUR
Accounts receivable	8.4B EUR	7.7B EUR	8.4B EUR
Other current assets	4.1B EUR	3.8B EUR	3.5B EUR
Current income tax assets	397.0M EUR	724.0M EUR	391.0M EUR
Cash and cash equivalents	7.7B EUR	7.4B EUR	8.7B EUR
Current assets	31.0B EUR	42.6B EUR	30.7B EUR
Non-current assets or disposal groups classified as held for sale	208.0M EUR	13.5B EUR	15.0M EUR
Total assets	126.8B EUR	132.8B EUR	126.5B EUR
Equity attributable to equity holders of Sanofi	71.4B EUR	77.5B EUR	74.0B EUR
Equity attributable to non-controlling interests	334.0M EUR	350.0M EUR	313.0M EUR
Total equity	71.7B EUR	77.9B EUR	74.4B EUR
Long-term debt	14.2B EUR	11.8B EUR	14.3B EUR
Non-current lease liabilities	1.5B EUR	1.6B EUR	1.8B EUR
Non-current liabilities related to business combinations and to non-controlling interests	585.0M EUR	569.0M EUR	501.0M EUR
Non-current provisions and other non-current liabilities	6.7B EUR	8.1B EUR	7.6B EUR
Non-current income tax liabilities	2.1B EUR	1.5B EUR	1.8B EUR
Deferred tax liabilities	1.7B EUR	2.2B EUR	1.9B EUR
Non-current liabilities	26.8B EUR	25.8B EUR	27.9B EUR
Accounts payable	7.4B EUR	7.6B EUR	7.3B EUR
Current liabilities related to business combinations and to non-controlling interests	0 EUR	72.0M EUR	208.0M EUR
Current provisions and other current liabilities	15.6B EUR	14.2B EUR	13.7B EUR
Current income tax liabilities	751.0M EUR	697.0M EUR	597.0M EUR
Current lease liabilities	272.0M EUR	261.0M EUR	275.0M EUR
Short-term debt and current portion of long-term debt	4.3B EUR	4.2B EUR	2.0B EUR
Current liabilities	28.3B EUR	29.2B EUR	24.2B EUR
Liabilities included in disposal groups classified as held for sale	54.0M EUR	2.1B EUR	13.0M EUR
Total equity and liabilities	126.8B EUR	132.8B EUR	126.5B EUR

Cash from operations⁸⁹¹⁰¹¹¹²⁵$10.8B in 2025+94% since 2018

Every line of the cash flow in the latest annual report, as filed.⁵

Period ending	2025-12-31	2024-12-31	2023-12-31
Net income attributable to equity holders of Sanofi	7.8B EUR	5.6B EUR	5.4B EUR
Net income excluding the exchanged/held-for-exchange Animal Health business	-2.9B EUR	-64.0M EUR	-338.0M EUR
Net income attributable to non-controlling interests	38.0M EUR	58.0M EUR	36.0M EUR
Share of undistributed earnings from investments accounted for using the equity method	290.0M EUR	82.0M EUR	293.0M EUR
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets	5.7B EUR	3.6B EUR	4.4B EUR
Gains and losses on disposals of non-current assets, net of tax	-352.0M EUR	-366.0M EUR	-364.0M EUR
Net change in deferred taxes	-2.4B EUR	-802.0M EUR	-1.2B EUR
Net change in non-current provisions and other non-current liabilities	-100.0M EUR	812.0M EUR	105.0M EUR
Cost of employee benefits (stock options and share-based payments)	313.0M EUR	278.0M EUR	260.0M EUR
Impact of the workdown of acquired inventories remeasured at fair value	126.0M EUR	10.0M EUR	9.0M EUR
Other profit or loss items with no cash effect on cash flows generated by operating activities	273.0M EUR	68.0M EUR	261.0M EUR
Operating cash flow before changes in working capital	8.8B EUR	9.2B EUR	8.9B EUR
(Increase)/decrease in inventories	-39.0M EUR	-477.0M EUR	-866.0M EUR
(Increase)/decrease in accounts receivable	-1.2B EUR	-28.0M EUR	-472.0M EUR
Increase/(decrease) in accounts payable	398.0M EUR	789.0M EUR	258.0M EUR
Net change in other current assets and other current liabilities	2.6B EUR	-899.0M EUR	1.5B EUR
Cash flows from (used in) operating activities, continuing operations	10.6B EUR	8.6B EUR	9.3B EUR
Net cash provided by/(used in) operating activities	10.8B EUR	9.1B EUR	10.3B EUR
Cash flows from (used in) operating activities, discontinued operations	189.0M EUR	474.0M EUR	987.0M EUR
Net cash provided by/(used in) operating activities of the discontinued Opella business	-3.5B EUR	-3.2B EUR	-2.9B EUR
Acquisitions of consolidated undertakings and investments accounted for using the equity method	-9.4B EUR	-1.9B EUR	-2.5B EUR
Acquisitions of other equity investments	-684.0M EUR	-623.0M EUR	-134.0M EUR
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax	0 EUR	0 EUR	42.0M EUR
Net change in other non-current assets	-80.0M EUR	-40.0M EUR	-224.0M EUR
Cash flows from (used in) investing activities, continuing operations	-12.8B EUR	-4.3B EUR	-5.0B EUR
Net cash provided by/(used in) continuing investing activities	-2.4B EUR	-4.4B EUR	-6.2B EUR
Cash flows from (used in) investing activities, discontinued operations	-36.0M EUR	-109.0M EUR	-1.2B EUR
Net cash inflow from the Opella transaction	10.4B EUR	0 EUR	0 EUR
Net cash provided by/(used in) investing activities of the discontinued Opella business (h)	177.0M EUR	187.0M EUR	195.0M EUR
to shareholders of Sanofi	-4.8B EUR	-4.7B EUR	-4.5B EUR
to non-controlling interests, excluding BMS	-38.0M EUR	-38.0M EUR	-56.0M EUR
Payments received/(made) on changes of ownership interest in a subsidiary without loss of control	0 EUR	0 EUR	-3.0M EUR
Additional long-term debt contracted	5.6B EUR	0 EUR	48.0M EUR
Repayments of long-term debt	-2.6B EUR	-671.0M EUR	-3.7B EUR
Repayments of lease liabilities	-333.0M EUR	-282.0M EUR	-253.0M EUR
Acquisitions of treasury shares and related tax effect	-5.0B EUR	-302.0M EUR	-593.0M EUR
Cash flows from (used in) financing activities, continuing operations	-8.2B EUR	-5.8B EUR	-8.0B EUR
Net cash provided by/(used in) continuing financing activities	-8.2B EUR	-5.8B EUR	-8.1B EUR
Cash flows from (used in) financing activities, discontinued operations	-48.0M EUR	-12.0M EUR	-4.0M EUR
Impact of exchange rates on cash and cash equivalents	-47.0M EUR	-13.0M EUR	-32.0M EUR
Effect of Reclassification of Discontinued Operation	167.0M EUR	-167.0M EUR	0 EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	216.0M EUR	-1.3B EUR	-4.0B EUR
Income tax paid	-2.9B EUR	-3.3B EUR	-2.6B EUR
Interest paid	-485.0M EUR	-587.0M EUR	-559.0M EUR
Interest received	331.0M EUR	447.0M EUR	547.0M EUR
Dividends received from non-consolidated entities	17.0M EUR	52.0M EUR	17.0M EUR
Net change in short-term debt and other financial instruments	-1.1B EUR	59.0M EUR	751.0M EUR
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax	847.0M EUR	1.5B EUR	807.0M EUR
Other cash flows	-422.0M EUR	110.0M EUR	895.0M EUR
Adjustments For Non Current Financial Assets and Deferred Tax Expense	45.0M EUR	-146.0M EUR	-1.0M EUR

Compare Sanofi with another company

How it started

Sanofi-Synthélabo

Sanofi was founded on February 15, 1973 as a subsidiary of Elf Aquitaine (a French oil company subsequently acquired by Total), when Elf Aquitaine took control of the Labaz group, a pharmaceutical company formed in 1947 by Sociéte Belge de l'Azote et des Produits Chimiques du Marly. Labaz had developed benziodarone in 1957.

In 1993, Sanofi made a move into the Eastern Europe market by acquiring a controlling interest in Chinoin, a Hungarian drug company whose 1992, sales totaled about US$104 million. In the same year, Sanofi made its first significant venture into the US, and strengthened its presence in Eastern Europe, by first partnering with Sterling Winthrop and then acquiring the prescription pharmaceuticals business in 1994. Sanofi was incorporated under the laws of France in 1994, as a société anonyme, a form of limited liability company.

Synthélabo was founded in 1970, through the merger of two French pharmaceutical laboratories, Laboratoires Dausse (founded in 1834) and Laboratoires Robert & Carrière (founded in 1899). In 1973, the French cosmetics group L'Oréal acquired the majority of its share capital. In 1991, Synthelabo acquired Laboratories Delalande and Laboratoires Delagrange and, as a result of that deal, picked up the product metoclopramide.

Sanofi-Synthélabo was formed in 1999 when Sanofi merged with Synthélabo. At the time of the merger, Sanofi was the second largest pharmaceutical group in France in terms of sales and Synthélabo was the third largest. The merged company was based in Paris, France.

The merged companies focused on pharmaceuticals, divesting several businesses soon after the merger, including beauty, diagnostics, animal health and nutrition, custom chemicals, and two medical equipment businesses.

From Wikipedia’s article on Sanofi, shared under CC BY-SA 4.0.³

Leadership

Who has led Sanofi, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chief financial officer

Jean-Baptiste Chasseloup de Chatillon2018–2024

20052010201520202025

Chief executive officerPaul Hudson Sep 2019 to now¹
Chief executive officerPaul Hudson Sep 1, 2019 to now¹
Chief executive officerOlivier Brandicourt Apr 2015 to Sep 2019¹
Chief financial officerJean-Baptiste Chasseloup de Chatillon 2018 to 2024¹

Board members and other officers (1)

Board memberSerge Weinberg¹

Products and brands

prescription drug

Listed on Wikidata.¹

Subsidiaries and ownership

Owners

L'Oréal 9.4%

Subsidiaries

Bioverativ
Chattem
Genzyme
Opella
Sanofi (Japan)
Sanofi Medley
Sanofi Pasteur
Sanofi-Aventis
Sanofi-Aventis Korea
Shantha Biotechnics
Theraplix
Winthrop
Zentiva
Zentiva Group
sanofi-aventis
Hoechst since 1999

Also owns

Infraserv Höchst 31.2%
Regeneron Pharmaceuticals 22.2%

From Wikidata.¹

Acquisitions

2011Acquired Genzyme¹
Dec 21, 2009Chattem became a subsidiary¹
1999Hoechst became a subsidiary¹
Succeeded Hoechst¹
Succeeded Rhône-Poulenc¹
Succeeded Synthélabo¹

Employees over time

2017106,566¹

Former names

SANOFI-AVENTISAug 30, 2004 to May 9, 2011⁶
SANOFI SYNTHELABO SAJan 8, 2001 to Aug 24, 2004⁶

Timeline

Sep 2019New chief executive Paul Hudson becomes CEO¹
Apr 2015New chief executive Olivier Brandicourt becomes CEO¹
Aug 20, 2004Founded Founded¹

Recent filings

Oct 1, 20266-K
Sep 17, 20266-K
Aug 25, 2026N-PX
Aug 6, 20266-K
Jul 30, 20266-K
Jul 30, 20266-K
Jul 28, 202613F-HR
Jul 27, 20266-K
Jul 22, 2026SCHEDULE 13G/A
Jul 17, 20266-K
Jul 7, 20266-K
Jun 30, 2026NT 11-K
Jun 30, 2026NT 11-K
Jun 30, 202611-K
Jun 30, 202611-K

Every filing from the last three years, summarized. The full record is on SEC EDGAR.²

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataSanofi on Wikidata
2
SEC EDGARSanofi filings on SEC EDGAR
3
WikipediaSanofi on Wikipedia
4
Wikimedia CommonsSanofi logo by Sanofi, Public domain
5
SEC EDGARSanofi 10-K for fiscal 2025
6
SEC EDGARSanofi filings on SEC EDGAR
7
Wikimedia CommonsSanofi photo by Tangopaso, Public domain
8
SEC EDGARSanofi 10-K for fiscal 2018
9
SEC EDGARSanofi 10-K for fiscal 2019
10
SEC EDGARSanofi 10-K for fiscal 2020
11
SEC EDGARSanofi 10-K for fiscal 2021
12
SEC EDGARSanofi 10-K for fiscal 2022